NCT06253377

Continuous Renal Replacement Therapy With Oxiris in Acute Kidney Injury and Sepsis

Exploring Clinical Management and Outcomes of Continuous Renal Replacement Therapy With Oxiris in Acute Kidney Injury and Sepsis

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 50 (actual)
• Sponsor: Nefro Consultoria de Doenças Renais Ltda · Network
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Accepted

Summary

It is an epidemiology study to explore outcomes in patients with acute kidney injury (AKI) and sepsis submitted to continuous renal replacement therapy (CRRT) with Oxiris™. Objectives: Describe the experience and outcomes in patients with sepsis and AKI treated receiving CRRT with the adsorption membrane filter Oxiris™

Detailed description

Study Background \& Rationale: Acute kidney injury (AKI) is common in patients with sepsis, occurring in 5-50%. It happens in the context of a critical illness requiring intensive care. Fifteen percent require renal replacement therapy as supportive therapy until the kidneys recover. Membrane-coated filters, such as Oxiris™, promote high filtration clearance of uremic toxins, but additionally removal of inflammatory mediators and bacterial liposaccharide (LPS) . Even though this potential mechanism should be expected to benefit septic and AKI patients, results have not been uniform. The investigators´ group has been prescribing CRRT for AKI treatment for the last 20 years, having performed more than 20 thousand procedures. The investigators´ group experience with Oxiris™ filter in CRRT started in 2018. The objective of the study is to describe the clinical operational management of CRRT with this kind of filter and to explore patients' outcomes.

Conditions

• Acute Kidney Injury
• Sepsis

Interventions

Type	Name	Description
DEVICE	Adsorption membrane filter Oxiris™	Continuous Renal Replacement Therapy with the adsorption membrane filter Oxiris™

Timeline

• Start date: 2023-12-08
• Primary completion: 2024-10-01
• Completion: 2025-04-01
• First posted: 2024-02-12
• Last updated: 2024-02-12

Locations

1 site across 1 country: Brazil

Regulatory

• FDA-regulated device study